5.00 USD
↗ 0.09 (1.83%)AT CLOSE (11:59 AM EDT)
Aclaris Therapeutics, Inc.
ACRSNASDAQ • USD
4.90
↘ 0.10 (1.98%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
4.90
↘ 0.10 (1.98%)
Market: CLOSED
ACRS is currently priced at $5.00. ACRS shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jun 26, 2026.
Open?$4.88
High?$5.14
Low?$4.80
Prev. Close?$4.91
Volume?8.8M
Avg. Volume?1.6M
VWAP?$4.97
Rel. Volume?5.52x
Bid / Ask
Bid?$4.80 × 2.2K
Ask?$5.00 × 5.0K
Spread?$0.20
Midpoint?$4.90
Valuation & Ratios
Market Cap?698.3M
Shares Out?139.7M
Float?121.4M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?4.86
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
685.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?2
Momentum?80
Short Sent.?49
Piotroski F-Score?2/9Weak
Altman Z-Score?-0.14Distress
Confidence?52%Low
Short InterestHigh
Short % of Float?7.33%Elevated
Short Interest?8.9M
Days to Cover?6.8
Free Float121.4M
Avg Daily Volume1.3M
Settlement Date2026-06-15
Financial Health
Current Ratio?4.03Strong
Quick Ratio?4.03Strong
Cash Ratio?1.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.86FAIR▾
Peers100
S&P38
P/S?83.46HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-8.6CHEAP▾
S&P97
EV/Sales?80.04HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-48.5%WEAK▾
S&P3
ROA?-35.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-51986000
Enterprise Value?$669.7M
Fundamentals ratios updated end of day